Avanos Medical (AVNS) reported $701M in revenue for fiscal 2025, +1.9% year on year. That ranks #2007 by revenue among 2853 SEC filers and #191 in Healthcare. It posted a net loss of −$72.9M for the same year. Revenue has grown 2.4% a year on average since 2016 ($566M then). The fiscal 2025 balance sheet shows $1.1B in total assets, $89.8M in cash and $90.3M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $701M | +1.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $354M | −7.2% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$61.6M | +$335M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$72.9M | +$319M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $74.7M | −25.8% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquireProductiveAssets | $31.6M | +77.5% | FY20252025-12-31 |
| Total assetsAssets | $1.1B | −7.0% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $778M | −6.1% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $89.8M | −16.6% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $90.3M | −27.9% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $182M | $5.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Avanos Medical, Inc.
- Ticker
- AVNS
- Exchange
- NYSE
- SIC classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- Fiscal year end
- 12-31
- CIK
- 0001606498
Filings
- 10-QMay 5, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
- 10-QNov 5, 2025Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Pacira BiosciencesPCRX | $726M | $7.0M |
| Amphastar PharmaceuticalsAMPH | $720M | $98.1M |
| Supernus PharmaceuticalsSUPN | $719M | −$38.6M |
| Avanos MedicalAVNS | $701M | −$72.9M |
| Kiniksa Pharmaceuticals InternationalKNSA | $678M | $59.0M |
| SNDLSNDL | $677M | −$11.3M |
| Ultragenyx PharmaceuticalRARE | $673M | −$575M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Avanos Medical — Key figures |url=https://companiesranked.com/en/company/avanos-medical |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Avanos Medical — Key figures. CompaniesRanked. https://companiesranked.com/en/company/avanos-medicalBibTeX
@misc{companiesranked-en-company-avanos-medical-2026,
author = {{CompaniesRanked}},
title = {{Avanos Medical — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/avanos-medical}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001606498-26-000004 · February 24, 2026
{{cite web |title=Avanos Medical — Key figures — 10-K (0001606498-26-000004) |url=https://www.sec.gov/Archives/edgar/data/1606498/000160649826000004/avns-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.